PRAN - Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)
- Creatore Discussione pit701
- Data di inizio
-
Trading Day 19 aprile Torino - Corso Gratuito sull'investimento
Migliora la tua strategia di trading con le preziose intuizioni dei nostri esperti su oro, materie prime, analisi tecnica, criptovalute e molto altro ancora. Iscriviti subito per partecipare gratuitamente allo Swissquote Trading Day.
Per continuare a leggere visita questo LINK
the volture
OLL LLIINNN 📢📢
- Registrato
- 15/3/05
- Messaggi
- 10.186
- Punti reazioni
- 1.353
news,,,pareriiiiiiiiiiiiiiii
New Analysis of Prana's Clinical Trial Is Published in the Journal of Alzheimer's Disease
PBT2 Rapidly Improves Cognitive Performance in Alzheimer's Disease
NEW YORK, NY, Apr 19, 2010 (MARKETWIRE via COMTEX) -- Prana Biotechnology /quotes/comstock/15*!pran/quotes/nls/pran (PRAN 1.76, +0.41, +30.37%) (ASX: PBT) today announced that the authoritative scientific journal, Journal of Alzheimer's Disease, published an article on April 19 about Prana's lead drug candidate for Alzheimer's disease, PBT2, providing new analysis that it is effective in reversing dementia symptoms. The analysis, conducted by Professor Ashley Bush of The Mental Health Research Institute and The University of Melbourne, Australia, is based on tracking and ranking the responses of each individual patient, rather than only groups of patients, in Prana's PBT2's Phase IIa Alzheimer's disease clinical trial.
The results of the Phase IIa clinical trial, previously reported in The Lancet Neurology (July 2008 and an erratum in July 2009), showed that patients with mild Alzheimer's Disease treated with 250mg of PBT2, experienced an overall statistically significant improvement in Executive Function on a Neuropsychological Test Battery (NTB) within 12 weeks of treatment.
"Improvements in Executive Function is strongly related to improvement in daily function and to the quality of the daily life of patients," noted Dr. Jeffrey Cummings, Director, Alzheimer Disease Research Center, UCLA, and Chairman of Prana's Scientific Advisory Board.
"Very few drugs in clinical development have been able to bring these benefits to Alzheimer's Disease patients. I am very encouraged by these findings," concluded Dr. Cummings.
The Journal of Alzheimer's Disease paper reports the results of a post-unblinding analysis of the cognitive data that was not included in the original paper. The objective of the analysis was to see how individual patients who were receiving PBT2 responded compared to the individual patients who only received placebo. Importantly, even placebo patients showed some improvement in the tests because of a 'learning effect' of repeated testing. This new analysis has adjusted for this and demonstrated that:
-- 81% of patients on the 250mg dose of PBT2 responded better on the
Executive Factor NTB score than the best performing patient on
placebo.
-- 41% of patients on the 250mg dose of PBT2 responded better on the
overall Composite NTB score than the best performing patient on
placebo (of which Executive Function is one of 2 parts).
Asking the specific question, 'What is the probability that any patient who showed cognitive improvement was receiving PBT2?,' the paper reports there was a significant probability that:
-- Patients who improved in Executive Function were probably receiving
250mg of PBT2 (p=1.3 x 10-(9))
-- Patients who improved their Composite NTB were probably receiving
250mg of PBT2 (p=.0007)
New Analysis of Prana's Clinical Trial Is Published in the Journal of Alzheimer's Disease
PBT2 Rapidly Improves Cognitive Performance in Alzheimer's Disease
NEW YORK, NY, Apr 19, 2010 (MARKETWIRE via COMTEX) -- Prana Biotechnology /quotes/comstock/15*!pran/quotes/nls/pran (PRAN 1.76, +0.41, +30.37%) (ASX: PBT) today announced that the authoritative scientific journal, Journal of Alzheimer's Disease, published an article on April 19 about Prana's lead drug candidate for Alzheimer's disease, PBT2, providing new analysis that it is effective in reversing dementia symptoms. The analysis, conducted by Professor Ashley Bush of The Mental Health Research Institute and The University of Melbourne, Australia, is based on tracking and ranking the responses of each individual patient, rather than only groups of patients, in Prana's PBT2's Phase IIa Alzheimer's disease clinical trial.
The results of the Phase IIa clinical trial, previously reported in The Lancet Neurology (July 2008 and an erratum in July 2009), showed that patients with mild Alzheimer's Disease treated with 250mg of PBT2, experienced an overall statistically significant improvement in Executive Function on a Neuropsychological Test Battery (NTB) within 12 weeks of treatment.
"Improvements in Executive Function is strongly related to improvement in daily function and to the quality of the daily life of patients," noted Dr. Jeffrey Cummings, Director, Alzheimer Disease Research Center, UCLA, and Chairman of Prana's Scientific Advisory Board.
"Very few drugs in clinical development have been able to bring these benefits to Alzheimer's Disease patients. I am very encouraged by these findings," concluded Dr. Cummings.
The Journal of Alzheimer's Disease paper reports the results of a post-unblinding analysis of the cognitive data that was not included in the original paper. The objective of the analysis was to see how individual patients who were receiving PBT2 responded compared to the individual patients who only received placebo. Importantly, even placebo patients showed some improvement in the tests because of a 'learning effect' of repeated testing. This new analysis has adjusted for this and demonstrated that:
-- 81% of patients on the 250mg dose of PBT2 responded better on the
Executive Factor NTB score than the best performing patient on
placebo.
-- 41% of patients on the 250mg dose of PBT2 responded better on the
overall Composite NTB score than the best performing patient on
placebo (of which Executive Function is one of 2 parts).
Asking the specific question, 'What is the probability that any patient who showed cognitive improvement was receiving PBT2?,' the paper reports there was a significant probability that:
-- Patients who improved in Executive Function were probably receiving
250mg of PBT2 (p=1.3 x 10-(9))
-- Patients who improved their Composite NTB were probably receiving
250mg of PBT2 (p=.0007)
Allegati
the volture
OLL LLIINNN 📢📢
- Registrato
- 15/3/05
- Messaggi
- 10.186
- Punti reazioni
- 1.353
LOROCIU65
""ONLY THE BRAVE""
- Registrato
- 1/3/06
- Messaggi
- 31.837
- Punti reazioni
- 689
:la news e' positiva..ma sono in fase 2..anke nel miglioramneto della vita..
Ora e ' da capire..gli sviluppi..tempistiche..essendo fase 2..almeno 12
..mesi..
PER LA FASE SUCCESSIVI..DOVREI APPROFONDIRE...SUGLI STUDI IN ATTO..
Ora e ' da capire..gli sviluppi..tempistiche..essendo fase 2..almeno 12
..mesi..
PER LA FASE SUCCESSIVI..DOVREI APPROFONDIRE...SUGLI STUDI IN ATTO..
the volture
OLL LLIINNN 📢📢
- Registrato
- 15/3/05
- Messaggi
- 10.186
- Punti reazioni
- 1.353
1,92..mi rode a piu 40% ora 
poi directa manco gli stop permette qui
poi directa manco gli stop permette qui
vincent67
Nuovo Utente
- Registrato
- 29/4/04
- Messaggi
- 3.482
- Punti reazioni
- 76
potrebbe far gola......la news è molto positiva
vincent67
Nuovo Utente
- Registrato
- 29/4/04
- Messaggi
- 3.482
- Punti reazioni
- 76
sulla scia riparte acur
LOROCIU65
""ONLY THE BRAVE""
- Registrato
- 1/3/06
- Messaggi
- 31.837
- Punti reazioni
- 689
3.15...
LOROCIU65
""ONLY THE BRAVE""
- Registrato
- 1/3/06
- Messaggi
- 31.837
- Punti reazioni
- 689
..acur..per me..non e' finita..
gigante
Nuovo Utente
- Registrato
- 1/6/07
- Messaggi
- 45.451
- Punti reazioni
- 427
non e grafo che piace a me , ci sono troppe statiche:d:d:d